Recommended INN - List 63
rINN
briakinumab
daratumumab
davalintide
eptacog alfa pegol (activated)
fezakinumab
fresolimumab
girentuximab
insulin degludec
intetumumab
iodine (
124
I) girentuximab
lebrikizumab
ocriplasmin
rilotumumab
rontalizumab
semaglutide
sifalimumab
sothrombomodulin alfa
taliglucerase alfa
teprotumumab
varfollitropin alfa
▲
